Inventiva (NASDAQ:IVA) Shares Gap Down on Disappointing Earnings

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped down prior to trading on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $5.48, but opened at $5.21. Inventiva shares last traded at $5.4650, with a volume of 223,688 shares.

The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million during the quarter.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Barclays assumed coverage on shares of Inventiva in a report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 target price for the company. UBS Group assumed coverage on shares of Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price target on the stock. Leerink Partners assumed coverage on shares of Inventiva in a research report on Monday, January 12th. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $16.56.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC boosted its holdings in Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after acquiring an additional 9,212 shares during the period. Creative Planning bought a new position in Inventiva in the 2nd quarter valued at $32,000. Commonwealth Equity Services LLC increased its stake in Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after purchasing an additional 12,704 shares during the period. Virtu Financial LLC bought a new stake in shares of Inventiva during the fourth quarter worth $60,000. Finally, XTX Topco Ltd bought a new stake in shares of Inventiva during the fourth quarter worth $84,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

The stock’s 50 day moving average price is $6.26 and its 200-day moving average price is $5.37.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.